|
Treatment modalities and prognostic factors in patients with Masaoka-Koga stage III thymoma: a single center study
|
Z. Song   , M. Zhuang , Z. Jin , Y. Gao , B. Bian |
| Department of Oncology, The First People’s Hospital of Lianyungang, Lianyungang, China , bbx5720620@sina.cn |
|
|
Abstract: (721 Views) |
Background: Clinical stage and the ability to achieve comprehensive treatment were the prognostic features of thymoma. In the present study, we aimed to analyze the efficacy of different types of therapy in patients with Masaoka-Koga stage III thymoma. Materials and Methods: From 2001 to 2018, patients newly diagnosed with thymoma was retrospectively analyzed. The c2test was used to evaluate patient characteristics, the Kaplan-Meier method was used to calculate overall survival (OS), log-rank method was applied to examine the difference between groups, and Cox regression was used to analysis the potential prognostic factors of OS. Results: The median follow-up time was 50 months (range: 3-221 months), and median OS was 51 (range: 3-221) months. The radical surgery group had a significantly better OS than the palliative surgery group. The 5- year, 10-year OS were 88.2%, 74.4% in the radical surgery group, whereas the 5- year, 10-year OS were 51.8% and 32.4% in the palliative group. The 5-year OS in surgery followed by adjuvant radiotherapy group was higher than that of surgery alone group (82.8% vs 55.8%, P=0.033); similarly, the 10-year OS of the two groups were 64.2% and, 50.2%, respectively (P＜0.05). Multivariate analysis revealed that age < 50 years (HR [hazard ratio]: 0.264), radical resection (HR:0.134, P=0.000), and surgery combined with radiotherapy (HR:2.778, P=0.009) were independently associated with better OS. Conclusion: In Masaoka-Koga stage III thymoma, patients treated with radical surgery was capable of achieving better OS than patients treated with palliative surgery. Moreover, radical surgery was an independent factor of prognosis. |
|
| Keywords: Thymoma, surgery, radiotherapy, overall survival, prognosis. |
|
|
Full-Text [PDF 629 kb]
(179 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. 1. Zucali PA, De Vincenzo F, Perrino M, et al. (2021) Systemic treatments for thymic tumors: a narrative review. Mediastinum, 5: 24. [ DOI:10.21037/med-21-11] 2. Lim KE and Shen TC (2017) Surgical treatment of an invasive thymoma with intracaval and intracardiac extension. Acta Cardiol Sin, 33(2): 204-06. 3. Punga AR, Maddison P, Heckmann JM, et al. (2022) Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol, 21(2): 176-88. [ DOI:10.1016/S1474-4422(21)00297-0] 4. Chiappetta M, Lococo F, Pogliani L, et al. (2021) Masaoka-Koga and TNM Staging System in Thymic Epithelial Tumors: Prognostic Comparison and the Role of the Number of Involved Structures. Cancers (Basel), 13(21). [ DOI:10.3390/cancers13215254] 5. Odaka M, Tsukamoto Y, Shibasaki T, et al. (2017) Surgical and oncological outcomes of thoracoscopic thymectomy for thymoma. J Vis Surg, 3: 54. [ DOI:10.21037/jovs.2017.03.18] 6. Detterbeck FC and Zeeshan A (2013) Thymoma: current diagnosis and treatment. Chin Med J (Engl), 126(11): 2186-91. [ DOI:10.3760/cma.j.issn.0366-6999.20130177] 7. Detterbeck FC, Nicholson AG, Kondo K, et al. (2011) The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol, 6(7 Suppl 3): S1710-6. [ DOI:10.1097/JTO.0b013e31821e8cff] 8. Mariano C, Ionescu DN, Cheung WY, et al. (2013) Thymoma: a population-based study of the management and outcomes for the province of British Columbia. J Thorac Oncol, 8(1): 109-17. [ DOI:10.1097/JTO.0b013e318276241c] 9. Ried M, Marx A, Gotz A, Hamer O, et al. (2016) State of the art: diagnostic tools and innovative therapies for treatment of advanced thymoma and thymic carcinoma. Eur J Cardiothorac Surg, 49(6): 1545-52. [ DOI:10.1093/ejcts/ezv426] 10. Riedel RF and Burfeind WR, Jr. (2006) Thymoma: benign appearance, malignant potential. Oncologist, 11(8): 887-94. [ DOI:10.1634/theoncologist.11-8-887] 11. Lombe DC and Jeremic B (2015) A review of the place and role of radiotherapy in thymoma. Clin Lung Cancer, 16(6): 406-12. [ DOI:10.1016/j.cllc.2015.05.003] 12. Blumberg D, Port JL, Weksler B, et al. (1995) Thymoma: a multivariate analysis of factors predicting survival. Ann Thorac Surg, 60(4): 908-13; discussion 14. [ DOI:10.1016/0003-4975(95)00669-C] 13. Lindenmann J, Fink-Neuboeck N, Pichler M, et al. (2015) Stage-based treatment for thymoma in due consideration of thymectomy: a single-center experience and comparison with the literature. World J Surg Oncol, 13: 303. [ DOI:10.1186/s12957-015-0718-z] 14. Moon JW, Lee KS, Shin MH, et al. (2015) Thymic epithelial tumors: prognostic determinants among clinical, histopathologic, and computed tomography findings. Ann Thorac Surg, 99(2): 462-70. [ DOI:10.1016/j.athoracsur.2014.09.050] 15. Filosso PL, Venuta F, Oliaro A, et al. (2014) Thymoma and inter-relationships between clinical variables: a multicentre study in 537 patients. Eur J Cardiothorac Surg, 45(6): 1020-7. [ DOI:10.1093/ejcts/ezt567] 16. Ruffini E, Detterbeck F, Van Raemdonck D, et al. (2014) Tumours of the thymus: A cohort study of prognostic factors from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg, 46(3): 361-8. [ DOI:10.1093/ejcts/ezt649] 17. Funaki S, Shintani Y, Fukui E, et al. (2020) Surgical treatment strategies for invasive thymoma. J Thorac Dis, 12(12): 7619-25. [ DOI:10.21037/jtd-19-3045] 18. Yan J, Liu Q, Moseley JN, et al. (2016) Adjuvant Radiotherapy for Stages II and III Resected Thymoma: A Single-institutional Experience. Am J Clin Oncol, 39(3): 223-7. [ DOI:10.1097/COC.0000000000000044] 19. Hamaji M, Omasa M, Chen F, et al. (2014) Survival and treatments in patients with incompletely resected thymoma. Asian Cardiovasc Thorac Ann, 22(6): 712-8. [ DOI:10.1177/0218492313516116] 20. Bruni A, Stefani A, Perna M, et al. (2020) The role of postoperative radiotherapy for thymomas: a multicentric retrospective evaluation from three Italian centers and review of the literature. J Thorac Dis, 12(12): 7518-30. [ DOI:10.21037/jtd-2019-thym-09] 21. Mendogni P, Toker A, Moser B, et al. (2022) Surgical resection of Masaoka stage III thymic epithelial tumours with great vessels involvement: a retrospective multicentric analysis from the European Society of Thoracic Surgeons thymic database. Eur J Cardiothorac Surg, 62(4). [ DOI:10.1093/ejcts/ezac021] 22. Chen YD, Feng QF, Lu HZ, et al. (2010) Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. Int J Radiat Oncol Biol Phys, 78(5): 1400-6. [ DOI:10.1016/j.ijrobp.2009.09.066] 23. Rimner A, Yao X, Huang J, et al. (2016) Postoperative Radiation therapy is associated with longer overall survival in completely resected stage II and III thymoma-an analysis of the international thymic malignancies interest group retrospective database. J Thorac Oncol, 11(10): 1785-92. [ DOI:10.1016/j.jtho.2016.06.011] 24. Zhou D, Deng XF, Liu QX, et al. (2016) The effectiveness of postoperative radiotherapy in patients with completely resected thymoma: A meta-analysis. Ann Thorac Surg, 101(1): 305-10. [ DOI:10.1016/j.athoracsur.2015.06.034] 25. Hamaji M, Shah RM, Ali SO, et al. (2017) A meta-analysis of postoperative radiotherapy for thymic carcinoma. Ann Thorac Surg, 103(5): 1668-75. [ DOI:10.1016/j.athoracsur.2016.12.042] 26. Kondo K and Monden Y (2003) Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. Ann Thorac Surg, 76(3): 878-84; discussion 84-5. [ DOI:10.1016/S0003-4975(03)00555-1] 27. Jackson MW, Palma DA, Camidge DR, et al. (2017) The impact of postoperative radiotherapy for thymoma and thymic carcinoma. J Thorac Oncol, 12(4): 734-44. [ DOI:10.1016/j.jtho.2017.01.002] 28. Lee CM, Lee JD, Hobson-Webb LD, et al. (2016) Treatment of thymoma-associated myasthenia gravis with stereotactic body radiotherapy: A case report. Ann Intern Med, 165(4): 300-1. [ DOI:10.7326/L15-0469] 29. Baschnagel AM, Mangona VS, Robertson JM, et al. (2013) Lung metastases treated with image-guided stereotactic body radiation therapy. Clin Oncol (R Coll Radiol), 25(4): 236-41. [ DOI:10.1016/j.clon.2012.12.005] 30. Suh JW, Park SY, Lee CY, et al. (2019) Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate. PLoS One, 14(3): e0214291. [ DOI:10.1371/journal.pone.0214291] 31. Zhang Y, Li Z, Chen Y, et al. (2021) Induction strategy for locally advanced thymoma. Front Oncol, 11:704220. [ DOI:10.3389/fonc.2021.704220] 32. Kim ES, Putnam JB, Komaki R, et al. (2004) Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer, 44(3): 369-79. [ DOI:10.1016/j.lungcan.2003.12.010] 33. Marulli G, Lucchi M, Margaritora S, et al. (2011) Surgical treatment of stage III thymic tumors: a multi-institutional review from four Italian centers. Eur J Cardiothorac Surg, 39(3): e1-7. [ DOI:10.1016/j.ejcts.2010.11.026] 34. Weis CA, Yao X, Deng Y, et al. Contributors to the IRD (2015) The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol, 10(2):367-72. [ DOI:10.1097/JTO.0000000000000393] 35. Roden AC, Yi ES, Jenkins SM, et al. (2015) Modified Masaoka stage and size are independent prognostic predictors in thymoma and modified Masaoka stage is superior to histopathologic classifications. J Thorac Oncol, 10(4): 691-700. [ DOI:10.1097/JTO.0000000000000482] 36. Yamada Y, Yoshino I, Nakajima J, Miyoshi S, et al. Japanese Association for Research of the T (2015) Surgical Outcomes of Patients With Stage III Thymoma in the Japanese Nationwide Database. Ann Thorac Surg, 100(3): 961-7. [ DOI:10.1016/j.athoracsur.2015.04.059] 37. Ao YQ, Gao J, Wang S, et al. (2023) Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives. Mol Cancer, 22(1):70. [ DOI:10.1186/s12943-023-01772-4] 38. Zhao C and Rajan A (2019) Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk? Mediastinum, 3. [ DOI:10.21037/med.2019.08.02] 39. Cho J, Kim HS, Ku BM, et al. (2019) Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: An open-label phase II trial. J Clin Oncol, 37(24): 2162-70. [ DOI:10.1200/JCO.2017.77.3184] 40. Giaccone G, Kim C, Thompson J, et al. (2018) Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. The Lancet Oncology, 19(3): 347-55. [ DOI:10.1016/S1470-2045(18)30062-7] 41. Rajan A, Heery CR, Thomas A, et al. (2019) Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. Journal for immunotherapy of cancer, 7(1):2 69. [ DOI:10.1186/s40425-019-0723-9] 42. Noel G and Antoni D (2016) Proton therapy. Cancer Radiother, 20(6-7): 508-12. [ DOI:10.1016/j.canrad.2016.06.003] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Song Z, Zhuang M, Jin Z, Gao Y, Bian B. Treatment modalities and prognostic factors in patients with Masaoka-Koga stage III thymoma: a single center study. Int J Radiat Res 2024; 22 (2) :435-441 URL: http://ijrr.com/article-1-5465-en.html
|
